Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Transcriptome profiling reveals Th2 bias and identifies endogenous itch mediators in poison ivy contact dermatitis
Boyi Liu, Yan Tai, Boyu Liu, Ana I. Caceres, Chengyu Yin, Sven-Eric Jordt
Boyi Liu, Yan Tai, Boyu Liu, Ana I. Caceres, Chengyu Yin, Sven-Eric Jordt
View: Text | PDF
Research Article Immunology Neuroscience

Transcriptome profiling reveals Th2 bias and identifies endogenous itch mediators in poison ivy contact dermatitis

  • Text
  • PDF
Abstract

In the United States, poison ivy is the most common naturally occurring allergen that causes allergic contact dermatitis (ACD). The immune and pruritic mechanisms associated with poison ivy ACD remain largely unexplored. Here, we compared skin whole transcriptomes and itch mediator levels in mouse ACD models induced by the poison ivy allergen, urushiol, and the synthetic allergen, oxazolone. The urushiol model produced a Th2-biased immune response and scratching behavior, resembling findings in poison ivy ACD patients. Urushiol-challenged skin contained elevated levels of the cytokine thymic stromal lymphopoietin (TSLP), a T cell regulator and itch mediator, and pruritogenic serotonin (5-HT) and endothelin (ET-1) but not substance P (SP) or histamine. The oxazolone model generated a mixed Th1/Th2 response associated with increased levels of SP, 5-HT, and ET-1 but not TSLP or histamine. Injections of a TSLP monoclonal neutralizing antibody or serotonergic or endothelin inhibitors, but not SP inhibitors or antihistamines, reduced scratching behaviors in urushiol-challenged mice. Our findings suggest that the mouse urushiol model may serve as a translational model of human poison ivy ACD. Inhibiting signaling by TSLP and other cytokines may represent alternatives to the standard steroid/antihistamine regimen for steroid-resistant or -intolerant patients and in exaggerated systemic responses to poison ivy.

Authors

Boyi Liu, Yan Tai, Boyu Liu, Ana I. Caceres, Chengyu Yin, Sven-Eric Jordt

×

Figure 4

Validation of differential skin expression profiles of major cytokines and inflammatory marker genes in the oxazolone- and urushiol-induced ACD models.

Options: View larger image (or click on image) Download as PowerPoint
Validation of differential skin expression profiles of major cytokines a...
Real-time TaqMan qPCR data were arranged according to the major inflammatory and regulatory pathways. Gene transcripts in skin samples of oxazolone-induced (gray column) and urushiol-induced (white column) ACD mice were compared to levels in respective vehicle control mice (not shown), as determined by TaqMan real-time qPCR. β-Actin transcript levels were used as an endogenous control. Data in bar graphs are expressed as mean ± SEM. n = 5 mice/group. *P < 0.05, and **P < 0.01 vs. vehicle control group; #P < 0.05, and ##P < 0.01 vs. urushiol group. NS, no significance. One-way ANOVA followed by Tukey’s post hoc test was used for statistical analysis.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts